Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brexit

Set Alert for Brexit

Brexit: What Can The Life Sciences Industry Do About It?

With the UK seemingly heading towards an exit from the European Union in just two and a half years’ time, restrictions on the free movement of people, products and finance will impact the life science sector as much as, if not more than, many others.

Brexit United Kingdom Strategy

EMA Bidders, An Infographic On The Runners And Riders

Denmark, France, Ireland, Italy, Spain and Sweden have all have expressed a keen interest in hosting the European Medicines Agency once the UK leaves the EU. Bids are expected to be made sometime early next year, probably once the UK government triggers Article 50. There is at present no formal process for allocating an agency to a particular EU country, as this tends to be done via a process of political wrangling, so each prospective candidate will need to garner as much support for their bid as possible from the other member states.

Europe Brexit Policy & Regulation

Latest From Brexit

Europe's Pharma Tries To 'Keep Calm And Carry On' Amid Storm Strikes

Pharma leaders in the UK and Europe have had a stormy start to the week, as the UK government revealed its aim to leave the single market and the OECD issued a loud call for drug makers to restrain their prices.

Europe Brexit

2016 – The Pharma Year In Review

As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.

Brexit Commercial

What Does 2017 Hold For Pharma?

Few would argue that 2016 threw a number of curveballs into the global arena. With the New Year upon us, Scrip took a deep breath and asked a number of internal and external contributors across the pharma and biotech spectrum for their expectations for 2017.

Brexit Companies

Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?

Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.

Commercial Market Intelligence

O'Neill Warns Pharma Risks Backlash If Doesn't Engage In World AMR Pact

The globalized drugs industry needs to play ball and help find a solution to antimicrobial resistance or risk getting blamed for its failure and the resulting world health crisis.

United Kingdom BioPharmaceutical

Amid Brexit Chaos, UK PM Promises More R&D Funding, Lower Taxes, And Other Pro-Innovation Measures

The UK prime minister has promised more government R&D funding and other incentives in an attempt to reassure businesses worried by the uncertainty created by the Brexit vote. The move comes shortly before the Chancellor’s autumn statement and the next meeting of the UK EU Life Sciences Steering Group.

Brexit Innovation
See All
UsernamePublicRestriction

Register